ANERIS Trademark

Trademark Overview


On Monday, December 12, 2016, a trademark application was filed for ANERIS with the United States Patent and Trademark Office. The USPTO has given the ANERIS trademark a serial number of 87265055. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 27, 2020. This trademark is owned by Allergan Pharmaceuticals International Limited. The ANERIS trademark is filed in the Pharmaceutical Products category with the following description:

Oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals a...
aneris

General Information


Serial Number87265055
Word MarkANERIS
Filing DateMonday, December 12, 2016
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 27, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 25, 2017

Trademark Statements


Goods and ServicesOral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; Pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; Pharmaceutical preparations for the treatment and prevention of osteoporosis; Pharmaceutical preparations for the treatment and prevention of endometriosis; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Iron chelating pharmaceutical preparations; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceuticals and medicines affecting sensory organs; Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting urogenital organs; Pharmaceuticals and medicines affecting circulatory systems; Pharmaceuticals and medicines for the treatment of cardiovascular and blood pressure diseases and disorders; Pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceuticals and medicines for the treatment and prevention of irritable bowel syndrome; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Antibiotics; Antifungal preparations; Antivirals and Antiprotozoals; Pharmaceutical preparations for the prevention and treatment of bacterial infections; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of hypertension; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; Pharmaceuticals, namely, neuroprotective agents; antidepressants; pharmaceuticals, namely, antipsychotics; coronary vasodilating agents; Pharmaceutical preparations for the treatment of hypothyroidism; Pharmaceutical preparations for skin care used in connection with anti-aging, the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, facial aesthetic surgery, facial aesthetic reconstruction, breast aesthetics; topical antibiotics, anti-inflammatories, anti-infectives, anti-glaucoma eye drops and decongestant formulations; sterile ointments for medical use; ocular wetting solutions, artificial tears and formulations pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; Pharmaceutical preparations for the treatment of neurological disorders, muscle dystonias, smooth muscle disorders, autonomic nerve disorders, headaches, hyperhydrosis, sports injuries, cerebral palsy, spasms, tremors and pain; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lighteners; Pharmaceuticals and cosmeceuticals, namely, medicated skin cleansers, toners, moisturizers, skin rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, December 15, 2016
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Pharmaceuticals International Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressCoolock, Dublin 17
IE

Party NameAllergan Pharmaceuticals International Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressCoolock, Dublin 17
IE

Trademark Events


Event DateEvent Description
Monday, July 27, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 27, 2020ABANDONMENT - NO USE STATEMENT FILED
Friday, December 20, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 19, 2019EXTENSION 5 GRANTED
Friday, December 13, 2019EXTENSION 5 FILED
Thursday, December 19, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, December 13, 2019TEAS EXTENSION RECEIVED
Tuesday, March 19, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 15, 2019EXTENSION 4 GRANTED
Friday, March 15, 2019EXTENSION 4 FILED
Friday, March 15, 2019TEAS EXTENSION RECEIVED
Saturday, November 3, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 1, 2018EXTENSION 3 GRANTED
Thursday, November 1, 2018EXTENSION 3 FILED
Thursday, November 1, 2018TEAS EXTENSION RECEIVED
Wednesday, June 13, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 11, 2018EXTENSION 2 GRANTED
Monday, June 11, 2018EXTENSION 2 FILED
Monday, June 11, 2018TEAS EXTENSION RECEIVED
Friday, November 17, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 15, 2017EXTENSION 1 GRANTED
Wednesday, November 15, 2017EXTENSION 1 FILED
Wednesday, November 15, 2017TEAS EXTENSION RECEIVED
Wednesday, June 21, 2017NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 25, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 25, 2017PUBLISHED FOR OPPOSITION
Wednesday, April 5, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, March 13, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, March 13, 2017ASSIGNED TO EXAMINER
Thursday, December 15, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Thursday, December 15, 2016NEW APPLICATION ENTERED IN TRAM